The Sugar Molecule That Could Stop Multiple Sclerosis in Its Tracks.

Anyone who has dealt with multiple sclerosis—as a patient, a family member, or a clinician—understands why it has been dubbed the “disease of a thousand faces.” It exhibits distinct behaviors in nearly every individual it comes into contact with. Some people have it for decades, going through long stretches of relative normalcy interspersed with sporadic relapses. Others see their neurological function gradually deteriorate without interruption or remission, and there is currently little that medicine can do to slow the decline. A research team from Irvine, California, and Berlin, Germany, believes that a surprisingly simple molecule may eventually make a real difference for the second group, those with primary progressive multiple sclerosis.

N-acetylglucosamine, or GlcNAc, is the name of the molecule. It is a sugar compound that is found naturally in the human body and, surprisingly, in human breast milk. This gives it a biological credibility that is lacking in candidates that are solely synthetic. Through a process known as glycosylation, GlcNAc and related sugar molecules bind to proteins on cell surfaces inside of cells to form branched structures that control cell function and communication. The body already operates this system constantly; it is not novel biochemistry created in a lab. Researchers at Charité Berlin and UC Irvine have been trying to figure out what happens when that system is depleted and whether replenishing it could slow or even reverse the effects of multiple sclerosis on the brain.

GlcNAc & Multiple Sclerosis Research — Key Facts & People

A 2021 paper that was published in JAMA Neurology contained the first significant signal. GlcNAc levels in the blood serum of 120 patients were measured by Dr. Alexander Brandt, Professor Michael Demetriou, and colleagues from Berlin and Toronto. They discovered something startling: individuals with the progressive form of MS had much lower concentrations of the sugar than either healthy controls or patients with the more prevalent relapsing-remitting variant. Low serum GlcNAc was linked to the development of progressive disease, clinical disability, and neurodegeneration, according to a second study of 180 patients in Berlin. That is not evidence of causation. However, signals are difficult to ignore, and this opened a door that the research team has been cautiously navigating ever since.

GlcNAc’s apparent effects in brain tissue are what make it intriguing not only for diagnostic purposes but also for therapeutic purposes. Previous research on mice revealed that when GlcNAc was administered to nursing mice, it was transferred to their offspring through their milk, and the young animals displayed increased myelination, which is the process by which the protective sheath surrounding nerve cells forms and thickens.

The main issue with multiple sclerosis is essentially damaged myelin. It is attacked by the immune system, deteriorates, and the exposed axons—the electrical wiring in the brain—become weak and ultimately perish. The immune attack can be somewhat slowed by current MS medications. They all fail to restore the myelin that has already been lost. GlcNAc appears to fill that gap, at least in animal models, by stimulating the progenitor cells that initially produce myelin.

This was moved from animal models to real MS patients in the 2023 UCI clinical trial, and the results were cautiously startling. GlcNAc supplementation decreased several indicators of inflammation and neurodegeneration in an open-label, dose-escalation study, which is a significant limitation because both participants and researchers knew who was receiving the compound.

That would be significant on its own. However, this finding—that 30% of participants demonstrated a sustained improvement in neurological function—has truly captured the interest of the field. not stabilization. enhancement. The first author of the study, Dr. Michael Sy, stated unequivocally that current FDA-approved treatments can only slow progression. In patients who have already lost their function, none of them have consistently restored it. If GlcNAc is able to accomplish that, even in a small percentage of patients, it would be a significant departure from the current state of MS treatment.

This is a serious warning that shouldn’t be ignored. Because the trial was small, unblinded, and lacked a placebo control, the results are by definition preliminary. The researchers explicitly state that they are aware of this. Safety and dosage were examined in a Phase I trial with about thirty participants; the results have not yet been made public. The next step is larger, randomized, blinded studies, which require financial resources, time, and regulatory tolerance. A placebo effect, a change in behavior, or some other confounding factor that would be eliminated by a controlled design could all account for a portion of the 30% improvement that was seen. Promising open-label results that failed to withstand the scrutiny of a well-designed trial are common in medical history.

And yet. The GlcNAc story feels different from the typical parade of MS research announcements for some reason. This could be because the mechanism is so deeply rooted in the biology of the body, or it could be because the same team has been steadily building the evidence through mouse studies, biomarker studies, and now a first clinical trial without overpromising. It’s difficult not to think it’s worth paying attention to when scientists at two different universities on two different continents follow a single molecule so meticulously for so long without losing the thread. MS patients undoubtedly are.